Tesamorelin Frequently Asked Questions

Tesamorelin is a synthetic analogue of human GHRH (1-44) with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This structural modification enhances the peptide's stability and bioactivity compared to native GHRH. Peptides Pharma Tesamorelin is formulated at >99% purity in a lyophilized vial for research applications.

Tesamorelin binds to the GHRH receptor on pituitary somatotroph cells, stimulating the release of growth hormone. The trans-3-hexenoic acid modification enhances receptor binding affinity and resistance to enzymatic degradation. Clinical studies have shown Tesamorelin produces physiological, pulsatile GH release while significantly reducing visceral adipose tissue. These findings are from published clinical research.

Tesamorelin is studied in research related to visceral adiposity, lipodystrophy, body composition, growth hormone secretion, hepatic fat accumulation, cognitive function, and peripheral neuropathy. Its demonstrated effect on visceral fat reduction makes it particularly relevant to metabolic and body composition research.

Peptides Pharma Tesamorelin is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Every batch undergoes independent HPLC and mass spectrometry verification. Certificates of Analysis are available for all production batches.

Lyophilized Tesamorelin should be stored at 2-8°C, protected from direct light. Do not freeze. Once reconstituted, keep refrigerated at 2-8°C and use within 28 days. The modified GHRH structure provides reasonable stability under proper storage conditions.

Add bacteriostatic water slowly along the inner wall of the vial, allowing the lyophilized powder to dissolve without vigorous shaking. Gently swirl until fully dissolved. The volume of diluent used determines the final concentration for dosing calculations in your research protocol.

Reconstituted Tesamorelin stored at 2-8°C with bacteriostatic water is typically stable for up to 28 days. Use sterile technique when accessing the vial to maintain solution integrity and prevent microbial contamination.

Yes. Peptides Pharma Tesamorelin is supplied strictly for laboratory and research use. While Tesamorelin has received regulatory approval under certain brand names for specific clinical indications, Peptides Pharma's formulation is sold exclusively as a research compound and is not intended for therapeutic use.

All three are GHRH analogues but differ in structure and pharmacokinetics. Sermorelin is a 29-amino acid fragment with a short half-life. CJC-1295 is a 30-amino acid analogue with modifications for extended duration. Tesamorelin is a full-length 44-amino acid GHRH analogue with a trans-3-hexenoic acid modification. Each has a distinct pharmacological profile for different research applications.

Tesamorelin may be studied in combination with GH secretagogues such as Ipamorelin to achieve synergistic GH release through complementary receptor stimulation. Some research protocols also investigate Tesamorelin alongside metabolic peptides for body composition studies. Protocol design should be guided by published research literature.